In light of recent research the efficacy of current advanced life support treatments has been questioned. Ventricular fibrillation refractory to standard therapy is a presentation which may benefit from an updated approach to management, with the  1 -adrenoreceptor antagonist esmolol considered a therapy which may confer benefit. This systematic review and meta-analysis aimed to summarise the available evidence for esmolol in refractory ventricular fibrillation and identify if it may have any role in ACLS guidelines.
Introduction
Sudden Cardiopulmonary Arrest (SCA) is the cessation of spontaneous respirations and cardiac activity, resulting in a rapid loss of perfusion and without treatment, death (1, 2) . SCA frequently occurs in an emergency setting, whether out-of-hospital (OHSCA) or in the emergency department, requiring intervention from pre-hospital and emergency clinicians (3) . In the United Kingdom (UK) ambulance services attempt resuscitation in approximately 30,000 cases of OHSCA annually (4), in Canada 35,000 (5) , in Australia 15, 000 (6) and in the United States of America (USA) 356,000 (7) . Despite the extensive efforts of both pre-hospital and emergency clinicians, survival from OHSCA remains low at 5-12% depending on geographic region (4) (5) (6) (7) . Survival and neurological status post-resuscitation in SCA and OHSCA is most heavily associated with the immediate provision of Basic Life Support (BLS) interventions by bystanders or clinicians, including early chest compressions and defibrillation (8) (9) (10) .
However, some cases of SCA will not resolve with these initial measures.
In cases of SCA unresponsive to BLS interventions, Advanced Cardiac Life Support (ACLS) is initiated.
Traditionally, this has included the provision of advanced airway management in the form of endotracheal intubation or supraglottic airway placement as well as the commencement of pharmacological therapies such as epinephrine, amiodarone and lidocaine. However, recent research such as AIRWAYS-2 (11), PARAMEDIC-2 (12) and ALPS (13) , amongst others (14, 15) , has raised questions regarding the efficacy of current recommended ACLS therapies. Given the plethora of underlying physiological states which may precipitate SCA (2) , an individualised approach to the management of SCA has been advocated, as opposed to the didactic approach recommended by many ACLS algorithms. Ventricular Fibrillation (VF) refractory to initial defibrillation attempts is one such presentation of SCA which is hypothesised to likely benefit from a unique, tailored management strategy. as a minimum of three attempts at defibrillation and at least one dose of intravenous epinephrine and/or anti-arrhythmic therapy.
Intervention and Comparison
The intervention examined was intravenous esmolol at an initial bolus dose of 500mcg/kg, followed by an infusion of up to 100mcg/kg/min. Patients receiving this therapy were compared against patients who did not receive intravenous esmolol as part of their ongoing resuscitative efforts and had received a minimum of three attempts at defibrillation and at least one dose of intravenous adrenaline or anti-arrhythmic therapy.
Primary Outcome Measure
Patient survival to hospital admission.
Secondary Outcome Measures
Return of Spontaneous Circulation, patient survival to hospital discharge and patient neurological status at hospital discharge (measured with the Cerebral Performance Category Score, with scores of one or two considered favourable). 
CPC 1
Good cerebral performance: conscious, alert, able to work and may have mild neurologic or psychologic deficit
CPC 2
Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of daily life and able to work in sheltered environment
CPC 3
Severe cerebral disability: conscious, dependent on others for daily support because of impaired brain function
CPC 4
Coma or vegetative state: any degree of coma without the presence of all brain death criteria
CPC 5
Brain death: apnoea, areflexia, EEG silence
Search Strategies (Supplementary File)
In order to ensure potential evidence was obtained from both the fields of emergency and pre-hospital medicine a number of electronic databases were searched from their date of inception until November 
Selection of Studies
In determining the eligibility of retrieved studies for inclusion in this systematic review and metaanalysis, both authors performed a preliminary analysis of the title and abstract of each retrieved result from the electronic databases and grey literature. The pre-defined inclusion criteria were applied to the retrieved results and where doubt existed, the full-text was retrieved for assessment of possible inclusion.
If further uncertainty existed, an agreement was reached between authors.
Assessment of Methodological Quality
The assessment of methodological quality was performed by both authors, blinded to the others' verdict, employing previously validated checklists for assessment of study rigor.
 Randomised Controlled Trials were assessed using the CASP Checklist for Randomised
Controlled Trials (40)  Cohort Studies were assessed using the CASP Checklist for Cohort Studies (41)  Case-Control Series were assessed using the Joanna Briggs Institute Checklist for Case-Control Series (42)
Data Extraction
Both authors extracted data from results meeting the inclusion criteria utilising a standardised data extraction form. Data was pre-defined for extraction and is summarised in Table 1 . Where uncertainty existed regarding any data extracted from eligible results, the data extraction performed by each author were compared to ensure complete analysis. If data was unclear, lead authors from eligible studies were contacted for clarification. 
Assessment of Risk of Bias
Both authors assessed the risk of bias at the study level utilising the Cochrane Collaboration's Tool for Assessing Risk of Bias in randomised studies and using the ROBINS-I Tool in non-randomised studies.
When assessing the risk of bias across outcomes and the certainty of evidence the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was utilised. Where uncertainty existed agreement was reached between authors.
Synthesis of Results
Data collected was placed in a single spreadsheet for ease of access, with results combined using the
RevMan 5.3 Software and presented in a GRADE Evidence Profile table graciously provided by
GRADEpro on a student license. A random-effects model of meta-analysis was utilised, with a risk-ratio chosen for the presentation of results. A risk-ratio was chosen as although the overall survival from OHSCA is 5-12%, survival in cases of VF is commonly reported as greater than 10% (42) . Outcomes which occur at a rate of 10% or higher are often exaggerated by odds-ratios, with risk-ratios also easier to apply to clinical practice (43) . Heterogeneity was assessed utilising the I 2 statistic.
Results

Study Selection
The search strategies retrieved 17 results from The Cochrane Library, 24 results from CINAHL, 362
results from MEDLINE and 2,200 results from EMBASE. After removal of duplicates and screening of abstracts 12 full-text articles were assessed for inclusion. Two full-text articles ultimately fulfilled the pre-defined inclusion criteria. Searching the grey literature, unpublished literature and conference abstracts yielded two abstracts potentially relevant to this systematic review and meta-analysis, however, no contact information was provided for these abstracts and the results appeared to primarily relate to clinical settings outside SCA.
Figure 2: Study Selection Flow
Study Characteristics
No randomised or non-randomised controlled trials were identified in the systematic review, with the two studies identified both retrospective cohort studies. One study was conducted in the USA by Driver et al The results of quantitative data synthesis are shown in Figure 2 . Esmolol was seen to provide a benefit when compared against standard ACLS care in the primary outcome of survival to hospital admission Significant heterogeneity was observed in the computation of temporary ROSC, with otherwise no heterogeneity observed. Without access to raw patient data, no subgroup analyses were performed. 
GRADE Evaluation (Available in Supplementary Files)
All outcomes were considered to suffer from significant imprecision, with wide confidence intervals reported. Significant heterogeneity was observed in the computation of temporary ROSC, leading to this result being considered of very low certainty. Considering the dichotomous outcomes were unlikely to be affected by knowledge of treatment group, these were considered only at serious risk of bias given the failure to account for residual confounders. However, because evaluation of CPC score may potentially be influenced by knowledge of treatment group, this result was considered of very low certainty.
Discussion
A systematic review of the literature identified just two retrospective cohort studies examining the use of esmolol in rVF in human subjects. In completing a meta-analysis of the results from these studies, esmolol was found to improve patient survival to hospital admission, rates of temporary and sustained ROSC, favourable neurological status at hospital discharge and potentially survival to hospital discharge.
However, it is important to interpret these results with a degree of caution, as the certainty in this evidence is of low to very low (49) . No randomised, nor controlled, studies were identified, with both studies suffering from issues inherent in retrospective analyses including small sample sizes, This may also serve to mask the true benefit of esmolol, given the neurological damage associated with reduced cerebral perfusion pressures in prolonged resuscitation as well as the effect of increasing exogenous adrenaline administered throughout the resuscitative efforts which may hinder the antagonistic effects of esmolol.
Although the administration of a potentially life-saving medication, esmolol, in the setting of SCA and OHSCA could be considered low-risk, neither paper examined nor reported on adverse outcomes associated with the use of esmolol in rVF. In animal models, the use of intra-arrest esmolol for rVF was shown to have no deleterious effects on post-resuscitation cardiovascular stability (37, 38) . However, the potential for adverse events from the antagonism of  1 -adrenoreceptors in the post-resuscitation patient cannot be discounted without a strong evidence base in humans. Institutions already employing the use of esmolol in the management of rVF should continue to be diligent in assessing for adverse effects secondary to the use of esmolol.
Conclusion
This systematic review and meta-analysis assessing the role of esmolol in the management of refractory ventricular fibrillation suggests that the use of esmolol is associated with improved survival to hospital admission, increased temporary and sustained ROSC and improved favourable neurological status at hospital discharge, and likely improved survival to hospital discharge. However, the conclusions of this meta-analysis are considerably limited by the significant risk of bias present in both studies, issues in methodological quality and small sample sizes as well as a lack of analysis regarding the safety of esmolol in the setting of cardiopulmonary arrest. With the strength of evidence of the retrieved results considered low to very low, high-quality, prospective research, preferably in the form of co-ordinated randomised controlled trials between pre-hospital and emergency clinicians, is urgently needed to assess the true impact of esmolol in the setting of refractory ventricular fibrillation before esmolol can be recommended for use in routine clinical practice.
